![Hakan Goker](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Hakan Goker
Directeur/Membre du Conseil chez
Asceneuron SA
Profil
Hakan Goker currently works at Asceneuron SA, as Director, Forendo Pharma Oy, as Director, Merck Ventures BV, as Managing Director from 2021, STORM Therapeutics Ltd., as Director, iOnctura SA, as Director, Ribometrix, Inc., as Director, and Outrun Therapeutics Ltd., as Director from 2021.
Dr. Goker also formerly worked at Strategic Partners A, as Director, Macrophage Pharma Ltd., as Non-Executive Director, TocopheRx, Inc., as Director, SynAffix BV, as Director, Raze Therapeutics, Inc., as Director, Progyny, Inc., as Director, Artios Pharma Ltd., as Director, Atlas Venture LLP, as Associate from 2009 to 2010, and Aescap Venture Management BV, as Partner from 2012 to 2013.
Dr. Goker received his doctorate degree in 2000 from the University of London and undergraduate degree in 1996 from University College London.
Postes actifs de Hakan Goker
| Sociétés | Poste | Début |
|---|---|---|
Forendo Pharma Oy
 Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage drug company that develops novel treatments in women’s health | Directeur/Membre du Conseil | - |
Asceneuron SA
 Asceneuron SA BiotechnologyHealth Technology Develops therapeutics for neurodegenerative disorders | Directeur/Membre du Conseil | - |
Merck Ventures BV
 Merck Ventures BV Investment ManagersFinance Merck Ventures invests in companies located in the Netherlands. The firm targets companies operating in the fields of healthcare, healthcare drug development, life science tools, electronics and frontier technology & sustainability sectors. It provides financing for early stage capital requirements. | Private Equity Investor | 01/11/2013 |
iOnctura SA
 iOnctura SA BiotechnologyHealth Technology Develops therapies that extend health span for cancer patients | Directeur/Membre du Conseil | - |
STORM Therapeutics Ltd.
 STORM Therapeutics Ltd. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecule drugs through RNA biology for the treatment of cancer, inflammation, viruses and CNS diseases | Directeur/Membre du Conseil | - |
Outrun Therapeutics Ltd.
 Outrun Therapeutics Ltd. BiotechnologyHealth Technology Operates as a biotechnology platform for drug discovery | Directeur/Membre du Conseil | 01/04/2021 |
Ribometrix, Inc.
 Ribometrix, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease | Directeur/Membre du Conseil | - |
Anciens postes connus de Hakan Goker
| Sociétés | Poste | Fin |
|---|---|---|
Aescap Venture Management BV
 Aescap Venture Management BV Investment ManagersFinance Aescap's investment objective is to achieve a high rate of return for their investors while actively developing their portfolio firms' potential for commercial success. They invest in seed, start-up and early-stage biomedical firms based in Europe. They generally take majority stakes. They target firms working on treatment of human diseases. They seek a balanced portfolio composed of 15 to 20 firms. Within the biomedical area, Aescap looks for firms with marketplace leadership potential at a worldwide level. They prefer to invest in products which are sufficiently mature to yield realistic opportunities in the marketplace as well as assuring cash flow from licensing deals. Aescap is an active, hands-on investment partner. They work closely with the portfolio firm's management team to optimize human resources to build the business around innovative research. Aescap generally invests over a time frame of three to six years, depending on the type of investment. They seek transparency in legal and IP structure. | Private Equity Investor | 01/03/2013 |
Atlas Venture LLP
 Atlas Venture LLP Investment ManagersFinance Atlas Venture is a leading international venture capital investment manager specialized in sectors including life sciences, communications and information technology and investing in Europe and the US. The firm targets early-stage, science-based businesses and leads the first financing round, generally acquiring a significant minority stake which grants them board representation. They subsequently help recruiting a management team to carry the emerging business forward, typically towards international expansion. Atlas Venture also invests in later-stage operations such as corporate spin-offs and down financing. Investment criteria include leadership potential in a global high-growth market, market momentum and a proprietary disruptive technology or business model. In the technology industry, Atlas Venture focuses on components, systems, software and services. The group has invested in data warehousing, storage systems for digital media, core chips for mobile phones and MEMS-based displays for mobile devices. Their biotechnology investments focus on drug discovery. They have invested in blood-thinning agents, small interfering RNA, emerging cancer drugs and anti-infectives. Atlas Venture sources deals though a combination of top-down global market analysis and bottom-up local connections in their industries of choice, including contacts in the academic world. Their exit strategies are international and include M&A transactions and IPOs on a variety of exchanges. | Analyste en capital-investissement | 28/09/2010 |
| ░░░░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Hakan Goker
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
87
Relations au 1er degré
18
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 18 |
|---|---|
Atlas Venture LLP
Atlas Venture LLP Investment ManagersFinance Atlas Venture is a leading international venture capital investment manager specialized in sectors including life sciences, communications and information technology and investing in Europe and the US. The firm targets early-stage, science-based businesses and leads the first financing round, generally acquiring a significant minority stake which grants them board representation. They subsequently help recruiting a management team to carry the emerging business forward, typically towards international expansion. Atlas Venture also invests in later-stage operations such as corporate spin-offs and down financing. Investment criteria include leadership potential in a global high-growth market, market momentum and a proprietary disruptive technology or business model. In the technology industry, Atlas Venture focuses on components, systems, software and services. The group has invested in data warehousing, storage systems for digital media, core chips for mobile phones and MEMS-based displays for mobile devices. Their biotechnology investments focus on drug discovery. They have invested in blood-thinning agents, small interfering RNA, emerging cancer drugs and anti-infectives. Atlas Venture sources deals though a combination of top-down global market analysis and bottom-up local connections in their industries of choice, including contacts in the academic world. Their exit strategies are international and include M&A transactions and IPOs on a variety of exchanges. | Finance |
University of London
 University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University College London
 University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aescap Venture Management BV
Aescap Venture Management BV Investment ManagersFinance Aescap's investment objective is to achieve a high rate of return for their investors while actively developing their portfolio firms' potential for commercial success. They invest in seed, start-up and early-stage biomedical firms based in Europe. They generally take majority stakes. They target firms working on treatment of human diseases. They seek a balanced portfolio composed of 15 to 20 firms. Within the biomedical area, Aescap looks for firms with marketplace leadership potential at a worldwide level. They prefer to invest in products which are sufficiently mature to yield realistic opportunities in the marketplace as well as assuring cash flow from licensing deals. Aescap is an active, hands-on investment partner. They work closely with the portfolio firm's management team to optimize human resources to build the business around innovative research. Aescap generally invests over a time frame of three to six years, depending on the type of investment. They seek transparency in legal and IP structure. | Finance |
Strategic Partners A/S
 Strategic Partners A/S Pharmaceuticals: MajorHealth Technology Provides therapeutic treatment of of diseases caused by defects in the function and metabolism of proteins | Health Technology |
Asceneuron SA
Asceneuron SA BiotechnologyHealth Technology Develops therapeutics for neurodegenerative disorders | Health Technology |
TocopheRx, Inc.
 TocopheRx, Inc. Medical SpecialtiesHealth Technology Develops novel therapies for treatment of infertility | Health Technology |
SynAffix BV
 SynAffix BV BiotechnologyHealth Technology Develops antibody-drug conjugates | Health Technology |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage drug company that develops novel treatments in women’s health | Health Technology |
Raze Therapeutics, Inc.
 Raze Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops oncology therapeutics | Health Technology |
Progyny, Inc.
 Progyny, Inc. Miscellaneous Commercial ServicesCommercial Services Provides fertility and family building benefits solutions | Commercial Services |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures invests in companies located in the Netherlands. The firm targets companies operating in the fields of healthcare, healthcare drug development, life science tools, electronics and frontier technology & sustainability sectors. It provides financing for early stage capital requirements. | Finance |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecule drugs through RNA biology for the treatment of cancer, inflammation, viruses and CNS diseases | Health Technology |
Artios Pharma Ltd.
 Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products for cancer treatment | Health Technology |
Macrophage Pharma Ltd.
 Macrophage Pharma Ltd. BiotechnologyHealth Technology Engages in research and experimental development on biotechnology | Health Technology |
iOnctura SA
iOnctura SA BiotechnologyHealth Technology Develops therapies that extend health span for cancer patients | Health Technology |
Ribometrix, Inc.
Ribometrix, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease | Health Technology |
Outrun Therapeutics Ltd.
Outrun Therapeutics Ltd. BiotechnologyHealth Technology Operates as a biotechnology platform for drug discovery | Health Technology |
